Delivery Order SPE2DB22D1052-SPE2DB26FU7UV
- Not listed
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a $1,204.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a non-set-aside contract with an ultimate completion date of September 23, 2025, and performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a $3,443.09 delivery order by the Defense Logistics Agency (DLA) on August 15, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded contract, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $9,019.91 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award to a qualified vendor. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.73 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 MG/4 ML syringes (4 ML quantity) on August 12, 2025, with a completion date of August 13, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $6,266.96 on July 18, 2025, for the supply of MONOVISC 88 mg/4 mL syringes (4 mL quantity) under a firm fixed-price contract. The award, which carries an ultimate completion date of July 21, 2025, was funded by the Defense Logistics Agency's Medical Supply Chain division and performed at the company's corporate office location in Conshohocken, Pennsylvania. This non-competitive delivery order represents a continuation of...
- The Defense Logistics Agency awarded a delivery order valued at $3,757.37 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by July 30, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award was made on a firm fixed-price basis with no set-aside designation, indicating it was...
- SPE2DB22D1052Indefinite Delivery Contract
- SPE2DB22D1052-SPE2DB26FU7UVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Monovisc 88 mg/4 mL syringes with a ceiling value of $2,885.57. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract specifies an ultimate completion date of October 17, 2025, and identifies Conshohocken, Pennsylvania as the place of performance, which is also the location of AmerisourceBergen's corporate headquarters. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a leading pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying pharmaceutical products, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. Monovisc is a hyaluronic acid injection used for osteoarthritis treatment, reflecting the company's broad portfolio of medical supplies supporting Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 10/16/25 |